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Summary: We report on the diagnostic validity of the serum concentrations of the C-terminal propeptide of type I
procollagen (a marker of bone formation) and of the urinary excretion of deoxypyridinoline (a marker of bone
resorption) in a consecutive series of 89 tumour patients who were routinely examined by 99mTc-methylene bisphos-
phonate bone scintigraphy for detection of bone metastases.
Z score analysis reveals that the discriminating power of deoxypyridinoline is superior to that of calcium excretion
whereas the discriminating power of the C-terminal propeptide concentrations is inferior to that of bone alkaline
phosphatase values. Accuracy (as assessed by the area under the receiver-operating characteristic curve) was 0.75
for deoxypyridinoline and 0.82 for the C-terminal propeptide. Combination of both markers did not yield an increase
of accuracy (0.82) compared with the determination of the C-terminal propeptide concentrations alone. There
was a correlation (r = + 0.398; p < 0.0001) between C-terminal propeptide concentrations and deoxypyridinoline
excretion values in the group of 89 patients examined.
Further studies should be done to elucidate whether the determination of bone collagen turnover is suitable as a
screening procedure for detecting bone metastases.
Introduction
Type I collagen accounts for more than 90% of the or- Bone collagen is stabilized by the formation of pyridin-
ganic matrix of bone and is synthesized in the form of ium cross-links between the terminal, non-helical part of
a larger molecule, type I procollagen. This precursor type I collagen molecule and the helical region of an-
molecule contains additional sequences at both ends other. The cross-links found in bone collagen are formed
which are removed by specific proteinases before the from two hydroxylysine residues and one lysine residue
collagen molecules are assembled into fibers. The part (= deoxypyridinoline) or from three hydroxylysine resi-
removed from the carboxy^terminal end of the molecule dues (= pyridinoline). Deoxypyridinoline is found al-
enters the circulation where it can be measured by most exclusively in bone. The measurement of deoxy-
heterogeneous immunoassays (for review see I.e. (1)). pyridinoline excretion in urine should therefore specifi-
The concentration of this circulating C-terminal propep- cally reflect the degradation of bone collagen and hence
tide is thought to be directly associated with the number bone resorption (3).
of type I collagen molecules formed. Therefore it can be At present only preliminary results are available regard-
used to quantify type I collagen synthesis and hence ing the clinical significance of markers of bone collagen
bone formation (2). metabolism in tumour patients (4—6).
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Here we report on the diagnostic validity of the com-
bined assessment of bone collagen synthesis and degra-
dation with respect to detecting bone metastases in pa-
tients with different malignant tumours, comparing the
results with those of bone scintigraphy. The values of
the markers of bone collagen turnover were also com-
pared with those of alkaline phosphatase and urinary
calcium excretion which are the presently available mea-
sures for routine assessment of bone formation and re-
sorption, respectively.
Determination of creatinine concentration in urine was performed
using the fully mechanized analyzer Hitachi/BM 704 (Boehringer
Mannheim GmbH, Mannheim, Germany) by employing a kinetic
modification of the Jaffe procedure (7).
Urinary deoxypyridinoline excretion is given as μηιοΐ/ηιοί creati-
nine.
The following reference interval (2.5th-97.5th percentile) for
excretion of deoxypyridinoline in second morning urine samples
was established in apparently healthy pers'dhs (urine samples were
obtained between 8.00 and 10.00 a.m.): 1.3-9.3 (median: 4.6)
μπιοΐ/rnol creatinine (n = 99; 51 males and 48 females; range of
age: 19—62 years), liiere was no dependence of reference values
on sex (p > 0.1).
Materials and Methods
Characterization of patients by bone scintigraphy
We examined venous blood specimens and second morning urine
samples from a consecutive series of patients (34 males, 55 fe-
males; range of age: 26-84 years) with malignant diseases who
were routinely examined for the presence of bone metastases/pri-
mary bone tumours by 99mTc-methylene bisphosphonate bone scin-
tigraphy. Samples were collected between 8:00 and 10:00 a.m.
The diagnoses of the patients were cancers of breast (n = 33),
bronchia (n = 11), prostate (n = 7), kidney (n = 4), thyroid glands
(n = 2), oesophagus (n = 2), colon (n = 2), pharynx (n = 2),
tongue (n = 2), stomach (n = 1), tonsils (n = 1), uterus (n = 1)
and parathyroid glands (n = 1) as well as malignant melanoma
(n = 10), lymphoma (n = 5), Hodgkins's disease (n = 2), multiple
myeloma (n = 1), osteosarcoma (n = 1) and Ewing's tumour
(n = 1).
In compliance with the results of the scintigraphic examinations (as
independently judged by two experienced physicians for nuclear
medicine without knowledge of the corresponding biochemical
data) the patients were divided into the following groups:
(1) There are no pathological findings (= group 0; n = 29).
(2) According to the pathological findings (being detectable by
scintigraphy) the presence of bone metastases seems to be improb-
able (= group 1; n = 33), possible (= group 2; n = 13) and prob-
able (= group 3; n = 14), respectively.
All procedures involving human subjects were in compliance with
the Helsinki Declaration of 1975 (as revised in 1983).
Determination of the carboxy-terminal propeptide of
procollagen type I in serum
The concentration of the carboxy-terminal propeptide of procolla-
gen type 1 was determined by an enzyme immunoassay (Prolagen-
C™; Metra Biosystems, Inc., Palo Alto, CA [U.S.A.]). A calibra-
tion curve was constructed by a 4-parameter curve fitting algo-
rithm.
The following reference intervals (2.5th-97.5th percentile) for the
C-terminal propeptide in serum were established in apparently
healthy persons: (1) 50-180 μg/l (males, n = 51) (2) 50-145 μg/l
(females, n = 51). Range of age was 23-58 years (males) and
23-59 years (females).
Determination of the urinary excretion of
deoxypyridinol ine
Urinary concentration of deoxypyridinoline was determined by a
competitive enzyme immunoassay (Pyrilinks™-D; Metra Biosys-
tems Inc., Palo Alto, CA [U. S. A.]) employing a monoclonal anti-
body against deoxypyridinoline. A calibration curve was con-
structed by employing a 4-parameter curve fitting equation.
Measurement of total alkaline phosphatase activity
in serum
Activity of total alkaline phosphatase was measured at 4- 25 °C by
the optimized standard method conforming to the Recommenda-
tions of the German Society for Clinical Chemistry (8) using the
fully mechanized analyzer Hitachi/BM 704 (Boehringer Mannheim
GmbH, Mannheim, Germany).
Determination of bone alkaline phosphatase mass
concentration in serum
Bone alkaline phosphatase mass concentration was determined by
an immunoradiometric assay (Tandem®-R Ostase™; Hybritech
Inc., San Diego, CA [U.S.A.]; no. 3040 BE) employing two mo-
noclonal antibodies against two different epitopes of the bone alka-
line phosphatase molecule. A calibration curve was constructed by
linear interpolation between the plotted analytical results.
The following reference intervals (2.5th-97.5th percentile) for
bone alkaline phosphatase concentration in serum were established
in apparently healthy persons: (1) 3.8—21.3 μ§/1 (males, η ^ 51)
(2) 3.4-15.0 μg/l (females, n - 51). Range of age was 20-55
years (males) and 18—56 years (females).
Determination of the urinary excretion of calcium
Calcium excretion in second morning urine samples (see above)
was determined with an EFOX 5053 flame emission spectrometer
(Eppendorf Ger tebau Netheler H- Hinz GmbH, Hamburg, Ger-
many). Data are given in mol/mol creatinine (upper reference limit:
0.6 mol/mol).
Statistical analysis
The statistical methods employed inlcude the U-test according to
Wilcoxon, Mann & Whitney (two-tailed) for unpaired samples, lin-
ear regression equations as well as linear correlation coefficients
(9). The discriminating power was estimated by calculating the Z
scores (for explanations see tab. 1). The accuracy was determined
as the area under the receiver-operating characteristic curve.
Results
Discriminating power of C-terminal
propeptide concentrations and
deoxypyridinol ine excretion
in different groups of patients
Figure 1 shows the distributions of C-terminal propep-
tide concentrations and deoxypyridinoline excretion in
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Fig. 1 C-terminal propeptide values (fig. la) and deoxypyridino-
line excretion (fig. 1 b) in different groups of patients (as defined
under Materials and Methods).
Group 0 Group 1 Group 2 Group 3
Upper and lower lines indicate the 10th and 90th percentile, boxes
the 25th and 75th percentile and the line in the box the 50th percen-
tile.
Tab. 1 Discriminating power of biochemical markers of bone metabolism in different patient groups
(as described under Materials and Methods).
Ζ score3
Group 1
Group 2
Group 3
vs group 0
vs group 0
vs group 0
C-terminal
propeptide
fcgrt]
-0.76**
+0.85*
+2.12***
Deoxypyridinoline
excretion
[μπιο1/πιο1
creatinine]
+0.25
+ 1.11**
+2.75***
Bone alkaline
phosphatase
[μ§/1]
+0.43
+2.00*
+8.12***
Total alkaline
phosphatase
[U/l]
+0.13
+ 1.46**
+3.52***
Calcium
excretion
[mol/mol
creatinine]
+0.1
-0.4
-0.6*
a
 Ζ score =
* 0.01 < p < 0.05
- meangroup o p 0 (X = 1, 2, 3) ** 0.001 < p < 0.01
*** p < 0.001
the four groups of patients (as defined under Materials
and Methods). Z score analysis reveals that the discrimi-
nating power of deoxypyridinoline is superior to that of
calcium excretion whereas C-terminal propeptide con-
centrations are inferior to bone as well as total alkaline
phosphatase values if groups 1, 2 and 3, respectively,
are compared with group 0 (tab. 1). Four patients be-
longing to group 0 showed an increased urinary excre-
tion of deoxypyridinoline (among them a patient with
a carcinoma of the parathyroid glands). There was no
significant difference in the γ-glutamyl transferase activ-
ity concentrations in the four groups of patients
(p > 0.05).
Relationship between the examined
biochemical markers of bone metabolism
There was a correlation (r = + 0.398; p < 0.0001)
between C-terminal propeptide concentrations and de-
oxypyridinoline excretion values in the group of 89 pa-
tients examined. The same applies to the relationship
between C-terminal propeptide values and bone alkaline
phosphatase concentrations (p < 0.0001).
Apart from one patient with primary hyperparathyroid-
ism all patients were normocalcaemic. None of the urine
samples examined showed a urinary excretion of
calcium above the upper reference limit. A lack of corre-
lation was found between calcium excretion and all
other markers of bone resorption as well as bone forma-
tion (tab. 2).
Only 5 (22%) of 23 patients with excretion values of
deoxypyridinoline above the upper reference limit (9.3
Tab. 2 Correlation coefficients between C-terminal propeptide
concentrations, deoxypyridinoline excretion, bone alkaline phos-
phatase values and calcium excretion in serum/urine samples from
89 tumour patients with and without bone metastases.
Analytes Correlation
coefficients
C-terminal propeptide vs.
deoxypyridinoline excretion
C-terminal propeptide vs.
bone alkaline phosphatase
C-terminal propeptide vs.
calcium excretion
Bone alkaline phosphatase vs.
deoxypyridinoline excretion
Bone alkaline phosphatase vs.
calcium excretion
Deoxypyridinoline vs.
calcium excretion
r = + 0.398
p < 0.0001
r = + 0.529
p < 0.0001
r = - 0.036
p > 0.05
r = + 0.726
p < 0.0001
r = - 0.201
p > 0.05
r = - 0.125
p > 0.05
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μηιοΐ/mol creatinine) showed a concomitant rise of C-
terminal propeptide concentrations (> 180 μg/l [males]
and > 140 μ§/1 [females], respectively). For fiirther de-
tails see table 3 and figure 2.
Tab. 3 Comparison between C-terminal propeptide concentra-
tions and urinary excretion of deoxypyridinoline in 89 tumour pa-
tients {with and without bone metastases).
Number of sera η
with C-terminal
propeptide
concentrations
Number of urines with
deoxypyridinoline
excretion values
below above
the upper the upper
reference reference
limitb limitb
below the upper 79 (89%) 61(69%) 18(20%)
reference limit3
above the upper 10 (11%) 5 (5%) 5 (6%)
reference limit3
89(100%) 66(74%) 23(26%)
a
 180 μ°/\ [males] and 145 μ§/1 [females], respectively
b
 deoxypyridinoline 9.3 μηηοΐ/mol creatinine
Receiver-operating characteristic (ROC) plots
for C-terminal propeptide concentrations and
deoxypyridinoline excretion
To evaluate the efficacy of the bone collagen metabolism
markers for discriminating between groups 0 and 1 on
the one hand and groups 2 and 3 on the other, threshold
values were fixed corresponding to.· the 10th, 20th, ...,
90th percentile of the distribution of C-terminal propep-
tide concentrations and deoxypyridinoline excretion in
the group of 89 patients examined (fig. 3). For the com-
bination of the two markers an increase of at least one
marker above the 10th, 20th, ..., 90th percentile (see
above) was defined as a positive test result.
The accuracy was 0.82 for C-terminal propeptide values
and 0.75 for deoxypyridinoline excretion; a combination
of both markers did not further increase the value of
accuracy (0.82) compared with the determination of C-
terminal propeptide concentrations alone.
At a threshold value of 100 μg/l C-terminal propeptide
and of 7.7 μηιοΐ/mol creatinine for deoxypyridinoline
(corresponding to the 60th percentiles; see above) the
diagnostic efficiency (= sum of diagnostic sensitivity
and diagnostic specificity) for the combination of both
30
1 25
20
a, 15
o>
I 10
ρl·Ο
Ο 50 100 150 200 250
C-terminal propeptide [pg/l]
Fig. 2 Comparison between the urinary excretion of deoxypyrid-
inoline and C-terminal propeptide values in samples from 88 pa-
tients (with and without bone metastases).
Patients belonging to group 3 are indicated by stars, those belong-
ing to the other three groups by dots (one pair of serum/urine sam-
ples with a deoxypyridinoline excretion of 58 μπιοΐ/mol creatinine
and a C-terminal propeptide value of 210 μg/l is not presented in
the diagram). The horizontal and vertical lines, respectively, indi-
cate the upper reference limits (97.5th percentile) of deoxypyrid-
inoline excretion (deoxypyridinoline 9.3 μΐϊΐοΐ/mol creatinine) and
of C-terminal propeptide concentrations (175 μg/l) without taking
into consideration the dependence of C-terminal propeptide refer-
ence values on sex.
The relationship between the results of the two methods is given
by the following regression equation: Deoxypyridinoline excretion
[μηιοΐ/mol creatinine] = 4.332 + 0.033 χ C-terminal propeptide
concentration fog/I] (r = + 0.398; ρ < 0.0001).
0 20 40 60 80 100
100-Specificity [%]
Fig. 3 Receiver-operating characteristic (ROC) analysis of C-ter-
minal propeptide concentrations (indicated by circles), the urinary
excretion of deoxypyridinoline (designated by stars) and the com-
bination of both markers (indicated by squares) in patients belong-
ing to groups 2 and 3 (= according to scintigraphic criteria the
presence of bone metastases seems to be possible or probable)
(n = 27) vs patients belonging to groups 0 and 1 (= according to
scintigraphic criteria there are no pathological findings or the pres-
ence of bone metastases seems to be improbable) (n = 62).
Threshold values were fixed corresponding to the 10th, 20th, ...,
90th percentile of the distribution of C-terminal propeptide concen-
trations and deoxypyridinoline excretion in the group of 89 patients
examined. For the combination of the two markers an increase of
at least one marker above the 10th, 20th, ..., 90th percentile was
defined as a positive test result. For these threshold values the diag-
nostic sensitivities as well as the diagnostic specificities were cal-
culated.
Bur J Clin Chem Clui Biochem 1995; 33 (No 8)
Withold et al.: Bone collagen synthesis and degradation in tumour patients 483
markers was found to be maximal. For these threshold
values the diagnostic sensitivity was 93%; the diagnostic
specificity was 55%; the predictive value of a positive
test result was 47%; and the predictive value of a nega-
tive test result was 94%. The prevalence of patients be-
longing to groups 2 and 3 was 30%.
Discussion
It has previously been shown in patients with various
types of metabolic bone diseases that the serum concen-
trations of the C-terminal propeptide correlate with his-
tomorphometric variables of bone formation (2). Both in
cancer patients (6) as well as in patients with metabolic
bone diseases (2) a correlation of the C-terminal propep-
tide values with alkaline phosphatase activities was
found.
For the interpretation of C-terminal propeptide data it
has to be taken into account that a disturbed liver func-
tion may yield high serum concentrations probably due
to the involvement of liver endothelial cells in the meta-
bolic clearance of this molecule (2). In the present study
a major influence of liver function upon C-terminal pro-
peptide values can be excluded because no statistically
significant changes of γ-glutamyl transferase activity
concentrations were found between the patient groups
examined.
The reference interval for C-terminal propeptide serum
concentrations established by us essentially corresponds
to that previously described for a radioimmunoassay
method (1).
Our results show a high discriminating power of bone
alkaline phosphatase values for differentiating between
patients with and those without bone metastases, in con-
trast to the results of van Hoff et al. (10) as well as
Stieber et al. (11) who found no such statistically signifi-
cant difference. This difference may be due to the dif-
ferent localization of the primary tumours as well as due
to the different character of the bone lesions (osteoblas-
tic, osteolytic and mixed, respectively). Burlina et al.
(12) reported that the determination of bone alkaline
phosphatase using wheat-germ lectin precipitation is
more specific than total alkaline phosphatase in the iden-
tification of bone metastases whereas Cooper et al. (13)
showed that bone alkaline phosphatase mass concentra-
tions (as determined immuno-radiometrically) may be
elevated in patients with bone metastases while total al-
kaline phosphatase activities remain in the normal range.
In the present study Z score analysis revealed that bone
alkaline phosphatase has a higher discriminating power
than total alkaline phosphatase with respect to differenti-
ating between patients with and those without bone me-
tastases. This corresponds to previous findings of Gar-
nero & Delmas (14).
Osteocalcin, which is another marker of bone formation,
has also been found to be elevated in patients with bone
metastases (15, 16). Interestingly, a lack of correlation
has been shown in these patients between osteocalcin
levels and bone alkaline phosphatase values (12). How-
ever, two drawbacks of this measurable quantity have to
be taken into account when comparing the values with
those of bone alkaline phosphatase concentrations:
(a) Decreased renal function may cause increased values
of this analyte due to its low relative molecular mass
(17).
(b) Osteocalcin concentrations are characterized by a
marked diurnal rhythm (18).
To our knowledge there are no examinations concerning
other bone matrix proteins with respect to the diagnosis
of bone metastases (e. g., osteonectin or proteoglycans
[e.g. by employing the monoclonal antibody 5D4
against keratan sulfate]).
Bone formation and bone resorption (as assessed by the
determination of bone collagen turnover) are coupled in
the patients examined by us which is in concordance
with previous findings in tumour patients (4).
The urinary excretion of calcium did not correlate with
that of deoxypyridinoline, corresponding to findings in
breast cancer patients undergoing therapy with inhibitors
of osteoclast activity (19). This strongly supports the hy-
pothesis that calcium and deoxypyridinoline excretion
reflect different facets of bone destruction.
Increased excretion values of deoxypyridinoline in four
patients in spite of pathological findings being absent as
assessed by bone scintigraphy (4, 5) may be explained
as follows:
(a) one of these four patients showed primary hyperpara-
thyroidism which causes increased values of deoxy-
pyridinoline (20).
(b) the increase of pyridinium cross-links excretion may
reflect occult metastases for which the diagnostic sensi-
tivity of bone scintigraphy is too low.
(c) tumour patients being immobilized may result in
increased bone resorption (5).
(d) generalised bone resorption which is mediated by
parathyroid hormone-related protein may occur (21) but
seems to be rather improbable because all patients exam-
ined (apart from one case with primary hyperparathyro-
idism) were normocalcaemic.
Numerous studies have demonstrated that malignant
cells secrete many of the factors known to stimulate the
Eur J din Chem Clin Biochem 1995; 33 (No 8)
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proliferation and activity of osteoclasts and to produce
osteolysis (e.g., transforming growth factors, prosta-
glandins, tumour necrosis factors and interleukin-1 that
has previously been labelled Osteoclast-activating-
factor') (22-25). Further, osteoclast activation is a key
step in the establishment and growths of all bone meta-
stases (23). However, it must be taken into consideration
that all of these substances do act as paracrine factors
so that measuring these mediators in blood seems to
have minor diagnostic significance for monitoring of
bone diseases.
For the interpretation of the data presented here the
following aspects have to be taken into account:
(a) Detection of lesions by bone scintigraphy depends
upon uptake of radioisotopes into areas of new bone
formation whereas this method is not suitable for the
sensitive detection of lytic lesions (for review see 1. c.
(26)). To further enhance the diagnostic sensitivity bone
scan scintigraphy should be supplemented by other tech-
niques (e.g., bone marrow scintigraphy, nuclear mag-
netic resonance tomography and single photon emission
computer tomography). On the other hand suspicious
findings must be confirmed by X-ray examinations to
enhance the diagnostic specificity.
(b) The tumour patients examined by us are hetero-
geneous with respect to the localization of the primary
tumour as well as staging and grading which will affect
the prevalence of bone metastases as well as the charac-
ter of the metastatic bone lesions (osteoblastic, osteo-
clastic or mixed).
Comparison of patients with and those without bone me-
tastases (as detected by bone scintigraphy) yielded a sta^
tistically significant difference of the values of both bio-
chemical markers but there is a substantial overlap of
the values; for the urinary excretion of deoxypyridino-
line this has already been observed in cancer patients
(4,5).
• r
The urinary excretion of hydroxyproline has been pro-
posed as an index of bone resorption for the diagnosis
(27) and follow-up (28) of patients with malignant tu-
mours. However, several drawbacks limit the clinical
usefulness of this quantity for assessment of bone re-
sorption:
(a) hydroxyproline is not exclusively derived from the
bone;
(b) hepatic metabolism may alter urinary excretion val-
ues;
(c) the urinary excretion depends both upon dietary up-
take as well as upon the degradation of newly synthe-
sized collagen (29).
In patients with prostate cancer it has already been
shown that serial measurements of the urinary excretion
of pyridinium cross-links are suitable for monitoring of
clinical progression (29); the same applies to the deter-
mination of bone alkaline phosphatase activity in pa-
tients with breast cancer (11). Moreover, in patients with
tumour-induced osteolysis the urinary excretion of pyri-
dinium cross-links may be a useful quantity for monitor-
ing therapy with agents inhibiting osteoclast activity
(e.g., bisphosphonates) (19).
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